Nutritive fragments, proteins and methods
Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein. In some embodiments, the fragment comprises at least one of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein, that is equal to or greater than the corresponding ratio present in a benchmark protein such as whey, egg or soy protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
1. A method of providing a subject a nutritive composition that comprises an isolated nutritive protein fragment comprising a polypeptide sequence that is at least about 80% homologous to a fragment of a naturally-occurring protein sequence over the total length of the isolated nutritive protein fragment, wherein the polypeptide sequence is at least 25 amino acids in length, wherein the isolated nutritive protein fragment is less than or equal to 150 amino acids in length, wherein the polypeptide sequence comprises:
a. a ratio of branch chain amino acid residues to total amino acid residues of at least 24%;
b. a ratio of Leu residues to total amino acid residues of at least 11%; and
c. a ratio of essential amino acid residues to total amino acid residues of at least 49%,
and wherein the method comprises at least one of: (a) maintaining or increasing at least one of muscle mass, muscle strength, and muscle functional performance in the subject, (b) maintaining or achieving a desirable body mass index in the subject, (c) treating or reducing protein-energy malnutrition in the subject, (d) increasing thermogenesis in the subject, (e) inducing at least one of a satiation response and a satiety response in the subject, and (f) treating at least one of cachexia, sarcopenia, and frailty in the subject.
2. The method of claim 1 , wherein the method comprises maintaining or increasing at least one of muscle mass, muscle strength, and muscle functional performance.
3. The method of claim 1 , wherein the method comprises maintaining or achieving a desirable body mass index.
4. The method of claim 1 , wherein the method comprises treating or reducing protein-energy malnutrition.
5. The method of claim 1 , wherein the method comprises increasing thermogenesis.
6. The method of claim 1 , wherein the method comprises inducing at least one of a satiation response and a satiety response.
7. The method of claim 1 , wherein the method comprises treating at least one of cachexia, sarcopenia and frailty.
8. The method of claim 1 , wherein the isolated nutritive protein fragment has a simulated gastric digestion half-life of less than 10 minutes.
9. The method of claim 1 , wherein the polypeptide sequence comprises 0, 1, 2, or 3 cysteine residues, or wherein the isolated nutritive protein fragment comprises no disulfide bonds.
10. The method of claim 1 , wherein the isolated nutritive protein fragment does not comprise at least one of N-linked glycosylation and O-linked glycosylation.
11. The method of claim 1 , wherein the polypeptide sequence has a calculated solvation score of −20 or less.
12. The method of claim 1 , wherein the polypeptide sequence comprises an amino acid sequence selected from:
i. an amino acid sequence selected from a SEQ ID list;
ii. a modified derivative of an amino acid sequence selected from the SEQ ID list; and
iii. a mutein of an amino acid sequence selected from the SEQ ID list, wherein the SEQ ID list is SEQ ID NOs 4-8, 12-13, 15-18, 20-27, 30, 32-37, 40-42, 45-51, 53, 56-57, 59, 63-69, 71, 74-77, 79, 81, 83, 85, 87, 90, 93-96, 98, 101-102, 106-108, 110-112, 114-115, 117-123, 128-130, 134-137, 139-141, 145-147, 151, 153, 155, 157-159, 161-162, 168-169, 174-175, 177-182, 188-189, 194, 196-197, 199-202, 204-205, 207, 209, 211-212, 214-215, 218-219, 221-222, 225-226, 228, 231-234, 237, 239, 241-247, 249-251, 255, 259-260, 268, 270-271, 274-278, 280, 282-285, 287-288, 290, 292-294, 299, 301, 304-306, 308-310, 313, 315-323, 326-329, 331, 333-338, 341, 348-349, 351, 354, 356, 359-360, 363-369, 372-375, 378-379, 381-386, 388, 393-398, 401, 404-405, 407-408, 410-411, 413-417, 420, 422, 426-429, 431-433, 436, 438-439, 441, 444, 446, 448-449, 451, 453-457, 459, 462-468, 471-473, 477, 479, 481-483, 485-489, 492-493, 495, 497, 499, 501-504, 508, 511, 515-516, 522-523, 527-528, 530, 533-537, 539-541, 543-549, 551-552, 554-557, 559-560, 565-566, 568, 570, 574-576, 578-580, 582-584, 586-591, 594, 597, 603-607, 610-612, 614-615, 617-618, 620-622, 624, 626-629, 634-635, 639, 641, 643, 645, 651-652, 654-655, 657, 659, 663-666, 675, 677-678, 680-681, 684-686, 688-689, 692, 694-696, 701, 706-708, 712-714, 717-718, 721-723, 725, 729-731, 733, 735-736, 738, 740-741, 744, 746-748, 750-751, 753, 755, 757-759, 762-764, 766-767, 775-776, 780-781, 784-785, 787, 800-807, 809, 812-820, 835, 838-839, 844, 847-848, 850-851, 854, 857, 862-863, 866, 868, 871-873, 875-876, 878-880, 882, 884-885, 887, 889, 891-892, 894, 898, 901-910, 912, 915-920, 924-928, 930, 935, 937-938, 941-943, 945-948, 950, 956-960, 964-967, 969-970, 972-973, 975, 977-978, 981-982, 985-988, 990, 992-997, 999-1011, 1014-1021, 1024-1025, 1027-1028, 1030, 1032-1050, 1052-1053, 1055-1077, 1079-1080, 1082-1096, 1098-1106, 1108-1112, 1114-1115, 1117-1121, 1123-1180, 1182-1190, 1192-1205, 1207-1232, 1234-1239, 1241-1244, 1246-1259, 1261-1274, 1276, 1278-1282, 1284-1285, 1287-1324, 1326-1342, 1344-1346, 1348-1360, 1362-1374, 1376-1414, 2519-2532, 2535-2556, 2559-2568, 2574-2596, 2598-2599, 2601-2609, and 2612-2613.
13. The method of claim 1 , wherein the polypeptide sequence further comprises a polypeptide tag, optionally wherein the tag comprises a polyhistidine-tag.
14. The method of claim 1 , wherein the polypeptide sequence comprises at least one of each essential amino acid.
15. The method of claim 1 , wherein the nutritive composition further comprises at least one of a protein, a polypeptide, a peptide, a free amino acid, a carbohydrate, a fat, a mineral or mineral source, a vitamin, a supplement, an organism, a pharmaceutical, and an excipient, optionally wherein the free amino acid is selected from the group consisting of essential amino acids, non-essential amino acids, branch chain amino acids, non-standard amino acids and modified amino acids.
16. The method of claim 1 further comprising providing a second isolated nutritive protein or fragment thereof comprising a second polypeptide sequence that is at least about 80% homologous to a fragment of a second naturally-occurring protein sequence over the total length of the fragment of the second isolated protein fragment, wherein the second polypeptide sequence comprises a ratio of essential amino acid residues to total amino acid residues of at least 40% and at least one of: a ratio of branch chain amino acid residues to total amino acid residues of at least 18% and a ratio of Leu residues to total amino acid residues of at least 8%.
17. The method of claim 1 , wherein the composition is provided to the subject orally.
18. The method of claim 1 , wherein the polypeptide sequence comprises a ratio of essential amino acid residues to total amino acid residues of greater than 49% and at least one of: a ratio of branch chain amino acid residues to total amino acid residues of greater than 24% and a ratio of Leu residues to total amino acid residues of greater than 11%.
19. The method of claim 1 , wherein the polypeptide sequence has less than 50% global homology to a known allergen.